State of New Jersey Common Pension Fund D Raises Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

State of New Jersey Common Pension Fund D grew its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 8.2% during the fourth quarter, Holdings Channel reports. The firm owned 51,398 shares of the biotechnology company’s stock after purchasing an additional 3,912 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Sarepta Therapeutics were worth $4,956,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in SRPT. Vanguard Group Inc. lifted its holdings in Sarepta Therapeutics by 0.5% in the third quarter. Vanguard Group Inc. now owns 8,572,944 shares of the biotechnology company’s stock valued at $1,039,212,000 after acquiring an additional 41,465 shares during the period. Picton Mahoney Asset Management acquired a new stake in shares of Sarepta Therapeutics during the 3rd quarter worth about $2,576,000. WCM Investment Management LLC purchased a new stake in Sarepta Therapeutics in the 4th quarter worth approximately $600,000. Capula Management Ltd purchased a new position in Sarepta Therapeutics during the third quarter worth about $1,409,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Sarepta Therapeutics by 351.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,824 shares of the biotechnology company’s stock valued at $1,044,000 after purchasing an additional 8,427 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Insider Activity at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 761 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the transaction, the director now directly owns 7,516 shares in the company, valued at $923,941.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 761 shares of the firm’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the sale, the director now owns 7,516 shares of the company’s stock, valued at approximately $923,941.88. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of Sarepta Therapeutics stock in a transaction on Friday, March 8th. The shares were sold at an average price of $123.25, for a total transaction of $1,848,750.00. Following the completion of the sale, the director now owns 22,840 shares in the company, valued at approximately $2,815,030. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,096 shares of company stock worth $2,739,419. Company insiders own 7.40% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the company. Citigroup raised their price objective on Sarepta Therapeutics from $160.00 to $172.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. Barclays increased their target price on Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. Mizuho upped their price objective on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Wednesday, February 14th. Wedbush reissued an “outperform” rating and issued a $224.00 price target on shares of Sarepta Therapeutics in a report on Thursday, February 29th. Finally, UBS Group boosted their price target on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a report on Friday, March 1st. Four research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $158.38.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock traded up $1.38 during trading hours on Friday, reaching $128.77. 1,236,000 shares of the stock were exchanged, compared to its average volume of 997,301. Sarepta Therapeutics, Inc. has a twelve month low of $55.25 and a twelve month high of $159.89. The company has a market cap of $12.09 billion, a P/E ratio of -21.04 and a beta of 0.94. The company has a current ratio of 3.95, a quick ratio of 3.45 and a debt-to-equity ratio of 1.32. The stock has a 50 day moving average of $126.11 and a two-hundred day moving average of $110.47.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.50. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The business had revenue of $396.80 million during the quarter, compared to analyst estimates of $387.18 million. During the same quarter last year, the business earned ($1.24) EPS. The firm’s quarterly revenue was up 53.6% on a year-over-year basis. Equities analysts expect that Sarepta Therapeutics, Inc. will post 2.13 EPS for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.